Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Expands Indication For Pipeline Flex Embolization Device

Executive Summary

Medtronic's Pipeline Flex device is now labeled for treating patients with small or medium wide-necked brain aneurysms following US FDA approval for an expanded indication.

You may also be interested in...



Market Snapshot: Flow Diversion Sees Highest Growth Among Neurointerventional Embolization Systems

Our infographic spotlights key trends in the global market for cerebral aneurysm and arteriovenous malformation (AVM) embolization systems, which is expected to reach $1.2bn by 2022, a CAGR of 3.9% from $975m in 2017. Among the growth drivers is the improvement of imaging screening techniques in developed nations. While this has resulted in increased intervention for cerebral aneurysm and AVM embolization, routine screening is not practiced, even in developed nations. Embolic coils accounted for the majority of sales with an estimated 73% market share. Meanwhile, a growing number of improved and premium-priced products such coil-assisted stent products and advanced embolic coil designs and flow diversion products are driving up the total value of the market.

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9Bn By 2024 Amid Rising Chronic Disease

The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel